Industry News (Hemophilia)

Drug Approved for Hemophilia A and B

Published in Blood Weekly, May 17th, 1999

Novo Nordisk A/S, parent company of ZymoGenetics, which produces NovoSeven Coagulation Factor VIIa (Recombinant), recently announced approval of NovoSeven by the U.S. Food and Drug Administration (FDA) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to coagulation Factors VIII or IX.

Bruce Carter, Novo Nordisk and ZymoGenetics (Seattle, Washington) said, "Researchers at ZymoGenetics discovered and cloned the human gene for Factor VII, on which NovoSeven was eventually based, in 1983. ZymoGenetics continued research to show that Factor VII could be produced in recombinant form from this gene. The project was then transferred to Novo...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1999-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry